Pegylated integrated interferon mutant
聚乙二醇新型集成干扰素突变体
Report date: 2023/05/19 20:00:21
Base Information
Drug NamePegylated integrated interferon mutant
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Tri-Prime Gene Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China
Develop Information
Active CompaniesBeijing Biaiou Technology Development Co LtdBeijing Tri-Prime Gene Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active Indications
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A